In-vitro activity of levofloxacin, a new fluoroquinolone: Evaluation against Haemophilus influenzae and Moraxella catarrhalis

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 21-26

  Kitzis, M D ^a   Goldstein, F W ^a   Miegi, M ^a   Acar, J F ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CONFERENCE PAPER; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; OFLOXACIN; PEFLOXACIN;

EID: 0033045703     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.suppl_3.21     Document Type: Conference Paper

References (41)

1. Fang, G.-D., Fine, M., Orloff, J., Arisumi, D., Yu, V. L., Kapoor, W. et al. (1990). New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 69, 307-16.
2. Chodosh, S. (1991). Treatment of acute exacerbations of chronic bronchitis: state of the art. American Journal of Medicine 91, Suppl. 6A, 87S-92S.
3. Gwaltney, J. M., Scheid, W. M., Sande, M. A. & Sydnor, A. (1992). The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. Journal of Allergy and Clinical Immunology 90, 457-62.
4. Fass, R. J. (1993). Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. Journal of Antimicrobial Chemotherapy 32 Suppl. A, 17-27.
5. Diaz, I. & Bamberger, D. M. (1995). Acute sinusitis. Seminars in Respiratory Infections 10, 14-20.
6. Khan, W., Ross, S., Rodriguez, W., Controni, G. & Saz, A. K. (1974). Haemophilus influenzae type B resistant to ampicillin. A report of two cases. Journal of the American Medical Association 229, 298-301.
7. Tomeh, M. O., Starr, S. E., McGowan, J. E., Terry, P. M. & Nahmias, A. J. (1974). Ampicillin-resistant Haemophilus influenzae type b infection. Journal of the American Medical Association 229, 295-7.
8. Malmvall, B. E., Brorsson, J. E. & Johnson, J. (1977). In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis. Journal of Antimicrobial Chemotherapy 3, 374-5.
9. Percival, A., Corkill, J. E., Rowlands, J. & Sykes, R. B. (1977). Pathogenicity of and β-lactamase production by Branhamella (Neisseria) catarrhalis. Lancet ii, 1175.
10. Jacoby, G. A. (1994). Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clinical Infectious Diseases 18, 951-7.
11. Doern, G. V. (1996). Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy 38 Suppl. A, 59-69.
12. James, P. A., Lewis, D. A., Jordens, J. Z., Cribb, J., Dawson, S. J. & Murray, S. A. (1996). The incidence and epidemiology of β-lactam resistance in Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 37, 737-46.
13. Berk, S. L. & Kalbfleisch, J. H. (1996). Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 85-96.
14. Markowitz, S. M. (1980). Isolation of an ampicillin-resistant, non-β-lactamase-producing strain of Haemophilus influenzae. Antimicrobial Agents and Chemotherapy 17, 80-3.
15. Mendelman, P. M., Chaffin, D. O., Stull, T. L., Rubens, C. E., Mack, K. D. & Smith, A. L. (1984). Characterization of non-β-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrobial Agents and Chemotherapy 26, 235-44.
16. Barry, A. L., Pfaller, M. A., Fuchs, P. C. & Packer, R. R. (1994). In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centres in 1992 and 1993. Antimicrobial Agents and Chemotherapy 38, 2419-25.
17. Scriver, S. R., Walmsley, S. L., Kau, C. L., Hoban, D. J., Brunton, J., McGeer, A. et al. (1994). Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrobial Agents and Chemotherapy 38, 1678-80.
18. Goldstein, F. W. & Acar, J. F. (1995). Epidemiology of antibiotic resistance in Haemophilus influenzae. Microbial Drug Resistance 1, 131-5.
19. Goldstein, F. W., Kitzis, M. D., Nebbad, H., Miégi, M., Guerrier, M. L., Coutrot, J. F. et al. (1996). Susceptibility of β-lactamase negative ampicillin-resistant H. influenzae to β-lactam antibiotics. Seventh International Congress for Infectious Diseases, Hong Kong. Abstract 111.020. Exerpta Medica Medical Communications B.V.
20. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
21. Yamane, N., Jones, R. N., Frei, R., Hoban, D. J., Pignatari, A. C. & Marco, F. (1994). Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. Journal of Chemotherapy 6, 83-91.
22. Barry, A. L., Fuchs, P. C., Allen, S. D., Brown, S. D., Jorgensen, J. H. & Tenover, F. (1996). In-vitro susceptibility of Streptococcus pneumoniae to the D-and L-isomers of ofloxacin: interpretive criteria and quality control limits. Antimicrobial Agents and Chemotherapy 37, 365-9.
23. Eliopoulos, G. M., Wennersten, C. B. & Moellering, R. C. (1996). Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagnostic Microbiology and Infectious Disease 25, 35-41.
24. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin and clofazimine. Antimicrobial Agents and Chemotherapy 40, 2483-7.
25. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A mullicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriazone/cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
26. Cormican, M. G., Erwin, M. E., Marshall, S. A. & Jones, R. N. (1996). Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagnostic Microbiology and Infectious Disease 24, 155-60.
27. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. et al. (1992). In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
28. Cohen, M. A., Yoder, S. L. & Talbot, G. H. (1996). Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Diagnostic Microbiology and Infectious Disease 25, 53-64.
29. Dabernat, H., Delmas, C., Seguy, M. & Lareng, M. B. (1991). Comparative in vitro activity of Sparfloxacin against Haemophilus influenzae and Branhamella catarrhalis. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 544-5.
30. Simor, A. E., Fuller, S. A. & Low, D. E. (1990). Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 34, 2283-6.
31. Goa, K. L., Bryson, H. M. & Markham, A. (1997). Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 53, 700-25.
32. Ball, P. & Tillotson, G. (1995). Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety 13, 343-58.
33. Markus, A., Isert, D., Klesel, N. & Seibert, G. (1995). Killing activity of levofloxacin (LEV) and ciprofloxacin (CIP) against Streptococcus pneumoniae in vitro and in vivo. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract E30, p. 90. American Society for Microbiology, Washington, DC.
34. Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J. et al. (1991). Infectious complications with respiratory pathogens despite ciprofloxacin therapy. New England Journal of Medicine 325, 520-1.
35. Fish, D. N. & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 32, 101-19.
36. Andrews, J. M., Honeybourne, D., Jevons, G., Brenward, N. P., Cunningham, B. & Wise, R. (1997). Concentrations of levofloxacin (HR355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 40, 573-7.
37. Lee, L. J., Sha, X., Gotfried, M. H., Howard, J. R., Dix, R. K. & Fish, D. N. (1998). Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 18, 35-41.
38. Nagai, H., Yamasaki, T., Matsuda, M., Goto, Y., Tasiro, T. & Nasu, M. (1993). Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 46, Suppl. 3, 259.
39. Nakamori, Y., Miyashita, Y., Nakatani, I. & Nakata, K. (1995). Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 49, Suppl. 2, 418-9.
40. Nakamori, Y., Tsuboi, E., Narui, K., Nakatani, T. & Nakata, K. (1992). Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections. Japanese Journal of Antibiotics 45, 539-47.
41. Wise, R., Baldwin, D. R., Andrews, J. M. & Honeybourne, D. (1991). Comparative pharmacokinetic disposition of fluoroquinolones in the lung. Journal of Antimicrobial Chemotherapy 28, Suppl. C, 65-71.